Vemlidy (tenofovir alafenamide) / Gilead - LARVOL DELTA

Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study. (PubMed, AIDS Res Ther) - "In one of the first real-world analyses of weight changes among virologically suppressed individuals who switched to a DOR-containing regimen in the US, DOR was associated with statistically significant weight loss. Patterns of use of other antiretrovirals did not fully explain the observed weight loss. These findings are clinically meaningful given that most individuals included were overweight or obese at switch to DOR and that women were predominantly of perimenopausal or menopausal age."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease • Obesity

Recommendations for interpreting intraerythrocytic tenofovir-diphosphate and emtricitabine-triphosphate for PrEP adherence assessment. (PubMed, J Acquir Immune Defic Syndr) - "Proper interpretation of TFV-DP and FTC-TP in DBS requires accounting for the factors identified above to maximize the value of these measurements."

Journal

Comparative Efficacy and Safety of Tenofovir Alafenamide Vs. Tenoforvir Disoproxil Fumarate In Chronic Hepatitis B: Meta-Analysis of Randomized Controlled Trails (BSG 2025) - "TAF demonstrated comparable efficacy to TDF in HBV DNA suppression but showed superior outcomes in terms of ALT normalisation, bone mineral density preservation, and kidney function. However, TAF led to higher LDL cholesterol levels, which may require monitoring. These findings suggest that TAF could be a safer alternative to TDF for CHB patients, particularly in those at risk for bone and renal complications."

Retrospective data • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-naïve HIV-hepatitis B co-infection. (PubMed, Int J STD AIDS) - "Rates of HBeAg loss (63% vs 57%), HBeAg seroconversion (35% vs 29%), HBsAg loss (29% vs 27%), and HBsAg seroconversion (23% vs 16%) were comparable at 36 months of therapy.ConclusionThis real-life study showed that both TAF- and TDF-containing regimens are effective in co-infected patients. The rates of HBsAg loss seemed higher than those in HBV-monoinfected patients."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

Improvement in renal function after switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low estimated glomerular filtration rates. (PubMed, Ann Hepatol) - "There was a substantial difference in eGFR between ETV and TAF treatments at week 48. Gender, baseline eGFR, and medication (TAF/ETV) were all remarkably positive indicators of eGFR abnormalities. In patients receiving ETV, an early switch to TAF may result in the reversal of early-stage renal damage."

Journal • Hepatitis B • Infectious Disease • Inflammation

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov) - P=N/A | N=205 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial primary completion date: Apr 2025 ➔ Jul 2025 | Completed ➔ Active, not recruiting | Trial completion date: Apr 2025 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study. (PubMed, iScience) - "This study aimed to assess hepatitis B virus (HBV) reactivation, its impact on prognosis, and its management in patients with HBV-related hepatocellular carcinoma (HCC), who received hepatic arterial infusion chemotherapy (HAIC) plus tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and entecavir (HAIC+TKIs+ICIs+entecavir) treatments. The median progression-free survival and median overall survival of patients in the HBV non-reactivation group were significantly longer than those of patients in the HBV reactivation group (p < 0.001, p < 0.001). The additional treatment with tenofovir alafenamide fumarate can effectively manage the HBV reactivation and improve the survival of these HBV reactivated HCC patients."

Clinical • Journal • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Deep sequencing analysis of hepatitis B virus in patients with incomplete response to tenofovir alafenamide fumarate treatment. (PubMed, World J Hepatol) - "The deep sequencing analysis of HBV DNA and RNA and comparing the detection rates of mutations were useful for estimating responsible mutations for TAF-incomplete responses. Such analysis is needed to evaluate the association between mutations that emerge during TAF treatment and incomplete responses to TAF."

Journal • Hepatitis B • Infectious Disease • Inflammation

Citrate accumulation during therapeutic plasma exchange in acute on chronic liver failure (ERA 2025) - " We describe a case of an 83-year-old Chinese lady with the background history of cirrhosis from chronic hepatitis B on Tenofovir Alafenamide (TAF), presented to our ED with nausea, giddiness, loss of appetite and jaundice for 2 weeks... Citrate accumulation may occur during TPE in a patient with liver impairment especially when FFP is used as the replacement fluid used. Close monitoring with repeated check of ionized calcium or prophylactic calcium infusion may avoid the occurrence of life threatening hypocalaemia during TPE in patient with liver impairment."

Acute Kidney Injury • Anorexia • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease

Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam. (PubMed, Antivir Ther) - "The study offers relevant evidence for policymakers to consider including TAF in the social health insurance package, with a focus on price negotiation. Future updates are needed as new evidence on the effectiveness and costs of treating chronic hepatitis B emerges."

HEOR • Journal • Hepatitis B • Infectious Disease • Inflammation

Strategies for preventing mother-to-child transmission in pregnant women with extremely high HBV DNA load (ChiCTR) - P=N/A | N=1050 | Not yet recruiting | Sponsor: Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University

New trial • Hepatitis B • Infectious Disease • Inflammation

Study on the Antiviral Efficacy and Safety of Nucleoside (Nucleotide) Analogues in Breast Cancer Patients with Chronic HBV Infection Undergoing Chemotherapy (ChiCTR) - P=N/A | N=324 | Not yet recruiting | Sponsor: Fujian Medical University Union Hospital; Fujian Medical University UNION Hospital

New trial • Breast Cancer • Hepatitis B • Infectious Disease • Inflammation • Oncology • Solid Tumor

A Multicenter, Prospective, Open-label, Non-inferiority Randomized Controlled Study on the Efficacy of Tenofovir Alafenamide Fumarate vs. Tenofovir Disoproxil Fumarate in Preventing Mother-to-Child Transmission of Hepatitis B Virus in Pregnant Women with High Viral Loads (ChiCTR) - P=N/A | N=210 | Not yet recruiting | Sponsor: Guangzhou Eighth People's Hospital; Guangzhou Eighth People's Hospital, Guangzhou Medical University

Head-to-Head • New trial • Hepatitis B • Infectious Disease • Inflammation

A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS). (PubMed, PLoS One) - "These findings unearth novel neurological, metabolic, and resistance - related risks, thereby necessitating a marked increase in clinical vigilance. The identification of signals related to cerebral infarction and dementia implies potential vascular/metabolic interplay, highlighting the importance of lipid monitoring among long - term tenofovir alafenamide (TAF) users. In response, healthcare providers should prioritize strengthening the monitoring of neurological symptoms and lipid profiles, reevaluating bone health assessment and management protocols especially in high - risk populations, and providing support to enhance patient adherence to mitigate resistance risks. This analysis offers crucial post - marketing evidence, which is instrumental in optimizing the risk - benefit balance of TAF in the long - term management of chronic hepatitis B virus (HBV) infection."

Adverse events • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia • Hepatitis B • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy-A New Horizon in Hepatitis B Therapy. Authors' Reply. (PubMed, Aliment Pharmacol Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy-A New Horizon in Hepatitis B Therapy. (PubMed, Aliment Pharmacol Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation

Kinetics and predictors of Hepatitis B surface antigen (HBsAg) loss after commencing HBV-active antiretroviral therapy (ART) in the setting of HIV-and chronic HBV co-infection. (PubMed, Clin Infect Dis) - "High HBsAg loss rates occur in people living with HIV and HBV early after commencing ART. Our study suggests that TAF-containing ART regimens may be preferable as first line therapy in HIV-HBV co-infection."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B. (PubMed, PLoS One) - "Significant increase in LDL-c and total cholesterol after switching to TAF were observed only in patients with prior TDF, but not in those with prior ETV or LAM. Careful monitoring of lipids after the switch may not be universally needed. Data regarding long-term cardiovascular outcomes are warrant."

Journal • Observational data • Cardiovascular • Hepatitis B • Hypertension • Infectious Disease • Inflammation

A global comparison of hepatitis B & C drug pricing. (PubMed, Ann Hepatol) - "HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities."

Journal • Pricing • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate. (PubMed, Drugs R D) - "Being an exploratory study, the findings of this substudy serve as potential avenues for further research."

Biomarker • Journal • Human Immunodeficiency Virus • Infectious Disease

TENOFOVIR ALAFENAMIDE TO ACHIEVE VIRAL SUPPRESSION ENABLING LISTING FOR KIDNEY TRANSPLANTATION IN A CASE OF CHRONIC HEPATITIS B INFECTION AND END STAGE KIDNEY DISEASE ON PERITONEAL DIALYSIS (ESPID 2025) - "Initial treatment with entecavir, using dosing adjustment extrapolated from adult guidelines, reduced HBV viral load from >9 million to 10–100,000 IU/ml. Learning Points/Discussion Achieving complete virological suppression in children with HBV high viraemia is challenging, particularly in ESKD with peritoneal dialysis, potentially compromising life-saving transplant options for these children. Despite limited dosing data, TAF monotherapy with careful TDM and safety monitoring appears effective for sufficient HBV suppression enabling kidney transplantation."

Clinical • Hepatitis B • Hepatitis C • Infectious Disease

Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men. (PubMed, Enferm Infecc Microbiol Clin (Engl Ed)) - "The present Spanish policy of PrEP is a cost-saving strategy. TAF/FTC and CAB are not cost-effective at current market prices."

HEOR • Journal • Human Immunodeficiency Virus • Infectious Disease

Integrative machine learning model for subtype identification and prognostic prediction in lung squamous cell carcinoma. (PubMed, Discov Oncol) - "We identified two LUSC subtypes by unsupervised clustering and developed an online tool for prognosis prediction using supervised machine learning models."

Journal • Non Small Cell Lung Cancer • Oncology • Squamous Cell Carcinoma • ACVRL1 • AOC3 • CD8 • MMP9 • TCF21 • TGM2 • TIMP3

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov) - P=N/A | N=205 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Apr 2025 | Trial primary completion date: Mar 2026 ➔ Apr 2025

Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

The HOPE Study: Characterizing Patients With Hepatitis B and C (clinicaltrials.gov) - P=N/A | N=550 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Dec 2025 ➔ Dec 2034 | Trial primary completion date: Jan 2025 ➔ Jul 2034

Trial completion date • Trial primary completion date • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation